ReviewEndocrine, metabolic & immune disorders drug targets2026
Current Status and Future Prospects of Immune Checkpoint Inhibitors Research in the Treatment of Multiple Myeloma.
Review in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ginsenoside F4 inhibits colorectal cancer progression by boosting dendritic cell maturation and remodeling the tumor microenvironment.World journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is an aggressive hematological tumor characterized by an abnormal proliferation of bone marrow plasma cells accompanied by an overproduction of monoclonal immunoglobulins. The clinical manifestations of MM are varied, with the main ones being anemia, bone pain, renal insufficiency, infections, hemorrhage, neurological symptoms, and hypercalcemia. Chemotherapy, targeted therapy, and stem cell transplantation can provide some relief to patients. However, with the immunodeficiency and immune tolerance that occurs with the progression of the disease, MM is still not completely curable. Immune checkpoint inhibitors (ICIs) provide a new strategy for the treatment of multiple myeloma by blocking the immune escape mechanism of tumor cells and enhancing the ability of T cells to recognize and kill tumors. Currently, immune checkpoint-related therapies such as PD-1/PD-L1, CTLA-4, and TIGIT have attracted extensive attention and research in the field of MM. Due to differences in the genetic characteristics of tumors, the composition of the tumor microenvironment, and the immune status of patients, these therapies face problems such as limited efficacy and immunotoxicity, and the treatment regimens still need to be further optimized. This review summarizes the current research status, challenges and future directions of targeted immune checkpoint therapies for multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.